BioSpace News Archive

electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary unaudited financial guidance for the first quarter of 2023.

INOVIO today announced that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo) (NCT04906629) was presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will present ten abstracts at the American Academy of Neurology (AAN) 75th Annual Meeting, to be held in Boston, MA, April 22–27, 2023.

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the presentation of a poster at the American Association for Cancer Research annual meeting, in Orlando, Florida, United States, between 14-19 April 2023.

AbbVie announced the European Commission approved RINVOQ® as the first oral Janus Kinase inhibitor for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Bright Peak Therapeutics announced the presentation of new data characterizing the highly targeted biological and therapeutic effects of BPT567 that contribute to its potent single agent anti-tumor activity at the American Association for Cancer Research Annual Meeting being held on April 14-19, 2023, in Orlando, FL.

Amneal Pharmaceuticals, Inc. announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023.

Amarin Corporation plc announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27.